Zea Biosciences Corp

Zea Biosciences Corp is a biotechnology firm that specializes in developing plant-based biologics and vaccines, aiming to enhance healthcare solutions through innovative plant-derived therapeutics. Founded in 2015, Zea Biosciences Corp operates from Walpole, US, focusing on plant biotechnology to create therapeutic solutions. The company was established by founder James Wilson and is currently led by CEO Charles Legg. Zea has been involved in one funding deal, with Valterra Partners investing in the company; however, the financial details were not disclosed.

Zea Biosciences specializes in a plant biotechnology platform known as Zea Lighthouse™, which focuses on the development and validation of biologics and vaccines derived from plants. This innovative platform harnesses the therapeutic potential of plants to address various diseases, thereby enhancing global healthcare access while reducing costs. Their core product offerings include plant-based medicinal solutions designed to undergo rigorous validation in collaboration with major academic institutions such as the University of Pennsylvania and Loma Linda University Health. The company primarily targets biopharmaceutical applications, serving a diverse client base that includes research institutions, healthcare providers, and pharmaceutical companies across North America and beyond.

Zea Biosciences generates revenue through strategic partnerships and research collaborations, particularly with research universities and healthcare organizations. Their revenue model is based on master research collaboration agreements (MRCAs) that facilitate joint development projects, involving shared funding and investment in the research and commercialization of plant-derived therapeutics. Transactions typically occur in the form of contracts that outline specific services rendered, including research, development, and potential licensing agreements for their proprietary technologies. While specific pricing plans for their offerings are not detailed, the structure likely includes performance-based milestones and research funding aligned with the progression of their plant-based medicinal products.

Zea Biosciences plans to expand its product line with new plant-derived therapeutics, although specific upcoming product launch dates have not been disclosed. The company is targeting expansion into new geographic markets, particularly North America, with plans to enhance their footprint by 2025. The recent investment from Valterra Partners will support these initiatives, focusing on research and development activities to drive innovation and commercialization of their plant-based products.